Current Report Filing (8-k)
February 22 2021 - 04:30PM
Edgar (US Regulatory)
0001270073
false
false
false
false
false
0001270073
2021-02-18
2021-02-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): February 18, 2021
Intercept
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
001-35668
(Commission
File
Number)
|
22-3868459
(IRS
Employer
Identification
No.)
|
10
Hudson Yards, 37th Floor
New
York, NY 10001
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (646) 747-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
ICPT
|
|
Nasdaq
Global Select Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On February 18, 2021, Jason Campagna, M.D., Ph.D., notified
Intercept Pharmaceuticals, Inc. (the “Company”) of his decision to resign from his position as the Company’s
Chief Medical Officer, effective March 5, 2021, in order to pursue other opportunities. Dr. Campagna’s resignation was not
the result of any disagreement regarding any matter related to the Company’s operations, policies, or practices.
Gail Cawkwell will serve as acting Chief Medical Officer pending
appointment of a permanent replacement.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INTERCEPT PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Jerome Durso
|
|
|
Name: Jerome Durso
|
|
|
Title: President and Chief Executive Officer
|
Date: February 22, 2021
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Mar 2023 to Mar 2024